On June 15, CSPC Group's paclitaxel for injection (albumin-bound) (II) (R&D code: SYHX2011) was approved for marketing by the National Medical Products Administration. This product is the world's first fast-dissolving albumin-bound paclitaxel formulation, backed by independently developed innovative formulation and manufacturing processes, and has obtained patent authorizations in multiple countries including China, the U.S., and Europe.
As a Class 2.2 modified new chemical drug, it represents a comprehensive upgrade in efficacy, safety, and clinical convenience, filling many of the clinical gaps of conventional albumin-bound paclitaxel, marking CSPC Group's technological breakthrough in the field of antitumor nanomedicines and offering a better chemotherapy option for patients with advanced breast cancer.
Figure 1. CSPC paclitaxel for injection (albumin-bound) (II) approved for marketing, source: NMPA website

01Breast Cancer and Taxanes
Breast cancer is a highly prevalent malignant tumor in China. According to a report by the National Cancer Center of China, there were about 376,000 new domestic cases in 2024, and the overall five-year survival rate for advanced patients is only around 20%, making the disease burden extremely heavy.

The indication approved this time is for metastatic breast cancer that has failed combination chemotherapy or has recurred within 6 months after adjuvant chemotherapy. Most of these patients have previously received anthracycline treatment, leaving limited subsequent treatment options.

At present, taxanes are cornerstone drugs in the comprehensive management of breast cancer. Albumin-bound paclitaxel has become a mainstream clinical option because it avoids the solvent-related toxicity of conventional formulations, but traditional dosage forms still have problems such as a high incidence of rash, cumbersome preparation procedures, and room for further efficacy improvement. Clinically, there is an urgent need for an upgraded product that combines strong efficacy, safety, and convenience.

02Mechanism of Action and Clinical Data
SYHX2011 underwent systematic optimization of its formulation. Without changing the effective drug dose, it substantially reduced the amounts of excipients such as human serum albumin and sodium caprylate, removed sensitizing impurities, and optimized the nanoparticle structure to enhance targeted accumulation in tumor tissue and stability, thereby strengthening antitumor effects through the tumor EPR effect.

The multicenter, randomized, double-blind Phase III trial supporting this approval enrolled a total of 459 patients with locally advanced and metastatic breast cancer.

The study data showed that, compared with conventional albumin-bound paclitaxel, the ratio of objective response rates assessed by the Independent Review Committee (IRC) and investigators was 1.38 (95% CI: 1.040, 1.842) and 1.33 (95% CI: 1.020, 1.745), respectively, both meeting the superiority criterion; progression-free survival was extended by 1.5 months (8.3 months vs 6.8 months; HR=0.73, one-sided P=0.0166), reducing the risk of disease progression by 27%, and the risk of death in terms of overall survival by 33%.

In terms of safety, the incidence of rash was reduced by 26.4%, the discontinuation rate due to adverse events decreased significantly, and patients' median dosing cycles and cumulative drug dose increased accordingly. Clinically, this product is a fast-dissolving formulation, shortening preparation time by 82% and greatly improving in-hospital treatment efficiency.

03Competitive Landscape in the Same Segment
At present, the domestic albumin-bound paclitaxel market already has generics from multiple companies approved for marketing, including CSPC Group, Hengrui Medicine, Qilu Pharmaceutical, and Kelun Pharmaceutical, and the competitive landscape is becoming increasingly mature. However, these products are all generics of traditional formulations and share common shortcomings in efficacy, safety, and preparation convenience.

The upgraded version launched by CSPC this time is a fast-dissolving albumin-bound paclitaxel proven superior in head-to-head studies; it builds a differentiated barrier through patented processes, efficacy advantages, and ease of use. Looking at global R&D pipelines, major pharmaceutical companies are mainly focusing on new paclitaxel formulations and exploration of combination regimens, while similar improved nanoformulations are mostly lagging behind this product.

In the breast cancer chemotherapy segment, traditional chemotherapeutics, targeted drugs, and immunotherapies form a combination treatment system, and this upgraded paclitaxel formulation can be flexibly paired with various drugs, offering broad application scenarios and strong market competitiveness.

Conclusion

The approval of Paclitaxel for Injection (Albumin-Bound) (II) is an important achievement of CSPC Group’s long-standing efforts in the oncology field. In the short term, leveraging its three core advantages of efficacy, safety, and convenience, this product will quickly be incorporated into the clinical treatment system for advanced breast cancer, optimizing patients’ overall chemotherapy regimens and improving treatment experience and outcomes. From a medium- to long-term perspective, supported by a mature commercialization channel, this product is expected to achieve gradual volume growth and further consolidate CSPC’s market position in the chemotherapy drugs sector. At the same time, this innovative formulation technology can also be extended to other solid tumor indications, broadening its application boundaries.
At the industry level, this product provides an excellent example of the improved upgrade of traditional chemotherapy drugs, driving domestic antitumor formulations toward greater precision, higher safety, and greater convenience, and helping continuously improve the standardized diagnosis and treatment of cancer in China.